Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL252026 | 0.88 | HPGD (0.79) | ALDH1A1USP2HPGDTSHRSIGMAR1 | |
| SCHEMBL7129676 | 0.88 | HPGD (0.79) | ALDH1A1USP2HPGDTSHRSIGMAR1 | |
| SCHEMBL27989163 | 0.86 | ALDH1A1 (0.85) | ALDH1A1USP2HPGDTSHRSIGMAR1 | |
| Hydrochloric Acid SCHEMBL1597472 | 0.86 | HPGD (0.76) | ALDH1A1USP2HPGDTSHRSIGMAR1 | |
| SCHEMBL21240918 | 0.85 | SLC6A7 (0.63) | AKR1C1ALDH1A1USP2TSHRRAB9A | |
| SCHEMBL14562621 | 0.85 | HPGD (0.63) | ALDH1A1USP2HPGDTSHRSIGMAR1 | |
| SCHEMBL29259559 | 0.84 | AKR1C1 (0.60) | AKR1C1TSHRPOLBCA12CA1 | |
| SCHEMBL3097149 | 0.82 | HPGD (0.66) | ALDH1A1USP2HPGDTSHRSIGMAR1 | |
| SCHEMBL14625978 | 0.82 | POLB (0.64) | AKR1C1ALDH1A1HPGDPOLBKDM4E | |
| SCHEMBL1938606 | 0.82 | HPGD (0.70) | ALDH1A1USP2HPGDTSHRSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026041790-A1 | DI(DISPIRODIAZATRIPIPERAZINE)-TRIAZINE DERIVATIVES AND THEIR USE FOR TREATMENT OR PREVENTION OF VIRAL INFECTIONS | Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts (DE) | 2026-02-26 | — | — | WO | disclosed |
| WO-2022124944-A1 | DI(DIAZONIADISPIRO[5.2.5.2]HEXADECAN)-5-NITROPYRIMIDINES FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | FEDERAL RESEARCH CENTRE “FUNDAMENTALS OF BIOTECHNOLOGY” OF THE RUSSIAN ACADEMY OF SCIENCES (RU) | 2022-06-16 | — | — | WO | disclosed |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2020-02-13 | — | — | US | disclosed |
| US-20170362262-A1 | A PROCESS FOR PREPARING HALOGENATED AZAINDOLE COMPOUNDS USING PYBROP | BRISTOL-MYERS SQUIBB COMPANY | 2017-12-21 | — | — | US | disclosed |
| WO-2017069661-A1 | PYRIMIDYL-DI(DIAZASPIRO-ALKANES) WITH ANTIVIRAL ACTIVITY | Limited Liability Company “Nearmedic Plus” (RU) | 2017-04-27 | — | — | WO | disclosed |
| CN-104169275-A | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2014-11-26 | — | — | CN | disclosed |
| CN-104159896-A | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2014-11-19 | — | — | CN | disclosed |
| WO-2012019003-A1 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20100093752-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| WO-2008049806-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-02 | — | — | WO | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| EP-0277836-B1 | THIAZOLIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR USE | Sankyo Company Limited (JP) | 1993-06-02 | — | — | EP | disclosed |
| US-4873255-A | REDUCE BLOOD GLUCOSE AND BLOOD LIPID LEVELS | SANKYO COMPANY LIMITED (JP) | 1989-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093752-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | AKR1C1 2198/4885ALDH1A1 1175/4885USP2 382/4885 |
| US-20170362262-A1 | A PROCESS FOR PREPARING HALOGENATED AZAINDOLE COMPOUNDS USING PYBROP | PAXBP1, AZI2, PML | AKR1C1 2720/4885ALDH1A1 4102/4885USP2 1976/4885 |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | OGFRL1, OPRL1, ORMDL3 | AKR1C1 578/4885ALDH1A1 395/4885USP2 3362/4885 |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | AKR1C1 1781/4885ALDH1A1 3257/4885USP2 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.